Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116064 | 0.82 | HSD17B10 (0.42) | HDAC1HSD17B10GLSHRH3 | |
| SCHEMBL29583126 | 0.80 | — | — | |
| SCHEMBL10527 | 0.80 | — | — | |
| SCHEMBL5021089 | 0.78 | CYP19A1 (0.59) | CYP19A1HRH3 | |
| Bromide SCHEMBL14801933 | 0.78 | HRH1 (0.59) | USP2HSD17B10HRH3 | |
| Iodide SCHEMBL22551708 | 0.78 | HRH1 (0.59) | USP2HSD17B10HRH3 | |
| Hydrochloric Acid SCHEMBL28050227 | 0.78 | ALDH1A1 (0.62) | USP2HRH3 | |
| SCHEMBL11564094 | 0.78 | HRH1 (0.59) | USP2HSD17B10HRH3 | |
| SCHEMBL30101413 | 0.78 | HRH1 (0.59) | USP2HRH3 | |
| Ammonia Solution, Strong SCHEMBL1509120 | 0.78 | HRH1 (0.59) | USP2HSD17B10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | CYP19A1 1130/4885USP2 2134/4885HDAC1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.